Dose Escalation Study of KB001 in Cystic Fibrosis Patients Infected With Pseudomonas Aeruginosa

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

April 30, 2009

Conditions
Cystic Fibrosis
Interventions
BIOLOGICAL

KB001

Single-dose, 3mg/kg or 10mg/kg dose administered intravenously

OTHER

Placebo

Placebo single-dose administered intravenously

Trial Locations (11)

15213

Children's Hospital of Pittsburgh, Pittsburgh

21287

Johns Hopkins University, Baltimore

35233

University of Alabama, Birmingham

43205

Nationwide Children's Hospital, Columbus

44106

Case Western Reserve University, Cleveland

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

55455

University of Minnesota, Minneapolis

63110

St. Louis Children's Hospital, St Louis

80045

University of Colorado, Aurora

84132

University of Utah, Salt Lake City

94305

Lucille Packard Children's Hospital at Stanford, Stanford

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Humanigen, Inc.

INDUSTRY